Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials
Zulfiqar A Bhutta(Aga Khan University), Audino Podda(Novartis (Italy)), Rachid Marhaba(Novartis (Germany)), Nelia Malubay(Research Institute for Tropical Medicine), Anand Kawade(King Edward Memorial Hospital Research Centre), Ashish Bavdekar(King Edward Memorial Hospital Research Centre), Allan Saul(Novartis (Italy)), María Rosario Capeding(Research Institute for Tropical Medicine), Edison Alberto(Research Institute for Tropical Medicine), Alessandra Anemona(Novartis (Italy)), Sajid Soofi(Aga Khan University), Rana M. Qasim Khan(Novartis (Italy)), Atif Habib(Aga Khan University), Laura Martín(Novartis (Italy)), Elisa Marchetti(Novartis (Italy)), Sanjay Juvekar(King Edward Memorial Hospital Research Centre), Noshad Ali(Aga Khan University), Shabina Ariff(Heidelberg University)
Cited by 134